iPSC Cardiomyocyte Panel for Genetic Cardiotoxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development processes lack effective models to predict cardiotoxicity across diverse human populations due to the lack of genetic diversity in existing hERG channel assays, leading to unforeseen adverse drug reactions and costly drug withdrawals.
Innovation Solution
A platform using genome-edited human induced pluripotent stem cells (iPSC) cardiomyocytes with specific KCNH2 gene mutations to create a panel of cell lines that mimic interindividual genetic variations, allowing for comprehensive testing of drug toxicity and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monogenic cell lines from single individuals are used for hERG testing, then the assay is simple to perform, but it fails to capture interindividual genetic differences leading to poor prediction of cardiotoxicity in diverse populations
Solution Approach 1:
The invention segments the population into multiple genetically distinct groups by creating cell lines from multiple donors with different genetic backgrounds. Instead of using a single monogenic cell line, the patent divides the testing into multiple parallel cell line panels, each representing different genetic variants. This segmentation allows the assay to capture interindividual genetic differences while maintaining manageable complexity through standardized culture and testing protocols for each cell line type.
Solution Approach 2:
The invention creates a universal platform that can test multiple genetic variants simultaneously using the same assay protocol. The cell lines are designed to be universally applicable for hERG channel testing across different genetic backgrounds. This multi-functionality allows a single standardized assay to serve multiple purposes: testing drug toxicity across diverse populations, identifying genetic risk factors, and predicting adverse reactions without requiring separate specialized protocols for each genetic variant.
2Reliability
If comprehensive genetic diversity is introduced into hERG assays, then prediction of drug effects on diverse populations improves, but the cost and complexity of testing increases significantly
Solution Approach 1:
The invention performs preliminary actions by establishing and characterizing a panel of cell lines with known genetic variants before actual drug testing begins. The cell lines are pre-cultured, genetically characterized, and validated for hERG channel expression in advance. This preliminary preparation creates a ready-to-use platform where diverse genetic backgrounds are already established and standardized, eliminating the need to create and validate new cell lines for each drug test, thereby reducing the manufacturing burden during actual testing phases.
Solution Approach 2:
The invention changes key parameters of the testing system by transitioning from single-cell-line to multi-cell-line panels, and from testing individual genetic variants to testing comprehensive genetic diversity. The patent systematically varies genetic parameters (different donor backgrounds, different hERG variants) while maintaining controlled experimental parameters (standardized assay conditions, consistent drug concentrations). This parameter change approach enables comprehensive genetic diversity testing through systematic variation of genetic factors rather than ad hoc modifications, making the process more manageable and scalable.
3Reliability
If multiple cell lines with different genetic variants are used for testing, then interindividual responses to drugs can be detected, but the time required for comprehensive assessment increases
Solution Approach 1:
The invention maintains continuous useful action by establishing permanent, stable cell lines that can be repeatedly used for multiple drug testing campaigns. Instead of creating temporary cell cultures for each test, the patent develops enduring cell line panels that remain viable and genetically stable over time. These continuous cell lines can be passaged and stored, allowing the same genetic variants to be tested against multiple different drugs without re-creating the cell lines each time. This continuity eliminates repeated setup and validation time while maintaining the ability to detect interindividual responses across diverse genetic backgrounds.
Data Source
AI summary
This disclosure is in the field of cardiac diseases. For example, the disclosure provides a new platform comprising iPSC and cardiomyocytes carrying one or more gene mutations, and models to study the effect of those gene mutations on cardiomyocytes, and on drug toxicity. This platform is identified herein as PREDICT PLATFORM.